RxDoctor Payments Data

Tiffanie Do, MD

Hematology & Oncology · Irvine, CANPI 1194251710

Payments from drug & device makers

$1,275in general payments, 2019–2025

Across 29 payments — averaging $43.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$282
  • AstraZeneca$194
  • Sanofi$126
  • Seagen Inc.$126
  • Bristol Myers Squibb$112
  • Karyopharm Therapeutics Inc.$110
  • plus $325 from 6 others

What the payments were for

  • Food & beverage$1,275100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,275 in reported general payments places this provider in the 25th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$43,231
Medicare patients
12
Services billed
2,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate22$377,429
XtandiEnzalutamide20$243,621
Lenalidomide21$219,370
BrukinsaZanubrutinib15$158,451
NivestymFilgrastim-Aafi19$18,304
GranixTbo-Filgrastim12$5,640
Abiraterone Acetate22$3,009
Anastrozole90$2,506
Hydroxyurea20$580
Dexamethasone44$573
Ondansetron Hcl45$377
Prednisone33$309
Acyclovir15$288
Potassium Chloride13$218
Prochlorperazine Maleate13$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$194$377,42922 claims
PfizerNivestym$83$18,30419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →